Skip to main content

Table 4 Subgroup analysis of SARS-CoV-2 RNA recurrent positive

From: The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive

Subgroup

No. of participants

OR

95% CI

P value

P for interaction

Sex

 Female

202

1.05

1.01–1.09

0.011

0.789

 Male

209

1.06

1.01–1.10

0.018

Age (year)

 < 18

14

-

-

-

-

 ≥ 18

397

1.05

1.02–1.08

0.001

BMI (kg/m2)

 < 24

267

1.04

1.00–1.07

0.026

0.350

 ≥ 24

144

1.07

1.02–1.12

0.007

Clinical type

 Mild-to-moderate infection

349

1.05

1.02–1.09

 < 0.001

0.080

 Severe-to-critical infection

62

0.94

0.84–1.05

0.289

White blood cell count (tertile)

 Low (2.70–4.76)

134

1.09

1.04–1.15

0.001

0.176

 Middle (4.80–6.30)

140

1.03

0.99–1.07

0.144

 High (6.31–36.10)

137

1.05

0.99–1.10

0.115

Neutrophil count (tertile)

 Low (0.47–2.53)

133

1.10

1.03–1.17

0.004

0.223

 Middle (2.55–3.65)

141

1.03

0.99–1.08

0.176

 High (3.66–13.45)

137

1.07

1.01–1.13

0.023

Neutrophil percentage (tertile)

 Low (7.2–53.7)

137

1.00

0.95–1.06

0.899

0.112

 Middle (53.8–64.0)

137

1.09

1.02–1.17

0.011

 High (64.1–94.9)

137

1.06

1.00–1.13

0.052

Lymphocyte count (tertile)

 Low (0.16–1.27)

137

1.04

0.98–1.10

0.172

0.023

 Middle (1.28–1.78)

132

1.14

1.06–1.23

0.001

 High (1.80–8.22)

142

1.02

0.97–1.07

0.382

Lymphocyte percentage (tertile)

 Low (4.4–24.9)

137

1.04

0.98–1.11

0.153

0.738

 Middle (25.0–33.6)

137

1.06

1.01–1.12

0.015

 High (33.7–84.0)

137

1.03

0.98–1.09

0.193

Monocyte count (tertile)

 Low (0.03–0.38)

135

1.20

1.08–1.32

0.001

0.002

 Middle (0.39–0.53)

133

1.03

0.96–1.11

0.343

 High (0.54–2.66)

143

1.00

0.94–1.06

0.989

Monocyte percentage (tertile)

 Low (0.3–7.1)

134

1.15

1.05–1.26

0.003

0.036

 Middle (7.2–9.7)

138

1.10

1.01–1.21

0.028

 High (9.8–41.7)

139

1.01

0.94–1.08

0.847

Hemoglobin (tertile)

 Low (71–122)

136

1.09

1.01–1.17

0.018

0.673

 Middle (122–137)

133

1.05

0.99–1.11

0.123

 High (137–297)

142

1.06

1.00–1.13

0.035

Platelet count (tertile)

 Low (66–180)

137

1.04

0.98–1.11

0.191

0.871

 Middle (180–226)

137

1.05

1.00–1.11

0.032

 High (226–577)

137

1.06

1.01–1.12

0.021

Chronic diseases

 No

262

1.04

1.00–1.07

0.031

0.181

 Yes

149

1.08

1.02–1.13

0.004

Hypertension

 No

335

1.04

1.01–1.07

0.019

0.008

 Yes

76

1.17

1.06–1.29

0.002

Diabetes

 No

375

1.05

1.02–1.08

0.001

-

 Yes

36

-

-

-

Chronic pulmonary disease

 No

390

1.05

1.02–1.08

0.001

-

 Yes

21

-

-

-

Coronary heart disease

 No

393

1.05

1.02–1.07

0.001

-

 Yes

18

-

-

-

Chronic kidney disease

 No

406

1.05

1.02–1.08

0.001

-

 Yes

5

-

-

-

Chronic liver disease

 No

365

1.05

1.02–1.08

0.001

-

 Yes

46

-

-

-

Malignant tumor

 No

404

1.05

1.02–1.08

< 0.001

-

 Yes

7

-

-

-

No. of antiviral drugs

 0

78

1.10

0.97–1.25

0.133

0.688

 1

178

1.05

1.00–1.10

0.030

 ≥ 2

155

1.04

1.00–1.08

0.037

Glucocorticoid

 No

366

1.04

1.01–1.06

0.005

0.005

 Yes

45

1.78

0.80–3.94

0.158

  1. Clinical type, routine blood test and treatment were the conditions of the previous discharge
  2. Because of the small number of cases in the Age and underlying disease (Diabetes, chronic pulmonary disease, coronary heart disease, chronic kidney disease, chronic liver disease, malignant tumor) subgroups, it is failed to calculate the effect value, confidence interval and interaction P value
  3. Because 1 patient is chronic lymphoblastic leukemia, there are abnormal values at the maximum of white blood cell count, lymphocyte count and lymphocyte percentage
  4. CI confidence interval, OR odd ratio
Back to article page

Infectious Diseases of Poverty

ISSN: 2049-9957

Contact us